APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis B Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hepatitis B Drug Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchHepatitis B Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis B Drug Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Hepatitis B Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis B Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis B Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Hepatitis B Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hepatitis B Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hepatitis B Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hepatitis B Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hepatitis B Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hepatitis B Drug include Bristol-Myers Squibb, Gilead Sciences, Merck & Co. Inc., Mitsubishi Tanabe Pharma, AbbVie, GlaxoSmithKline, Roche, Novartis and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hepatitis B Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hepatitis B Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Hepatitis B Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatitis B Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hepatitis B Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hepatitis B Drug revenue, projected growth trends, production technology, application and end-user industry.

Hepatitis B Drug Segment by Company

Bristol-Myers Squibb

Gilead Sciences

Merck & Co. Inc.

Mitsubishi Tanabe Pharma

AbbVie

GlaxoSmithKline

Roche

Novartis

Johnson & Johnson

Hepatitis B Drug Segment by Type

Tenofovir

Telbivudine

Lamivudine

Entecavir

Adefovir

Others

Hepatitis B Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Others

Hepatitis B Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hepatitis B Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hepatitis B Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatitis B Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatitis B Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tenofovir Major Player Table 3. Telbivudine Major Player Table 4. Lamivudine Major Player Table 5. Entecavir Major Player Table 6. Adefovir Major Player Table 7. Others Major Player Table 8. Global Hepatitis B Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Pharmacies Major Player Table 10. Retail Pharmacies & Drug Stores Major Player Table 11. Others Major Player Table 12. Hepatitis B Drug Industry Trends Table 13. Hepatitis B Drug Industry Drivers Table 14. Hepatitis B Drug Industry Opportunities and Challenges Table 15. Hepatitis B Drug Industry Restraints Table 16. Global Hepatitis B Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Hepatitis B Drug Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Hepatitis B Drug Market Share by Region (2021-2026) Table 19. Global Hepatitis B Drug Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Hepatitis B Drug Market Share by Region (2027-2032) Table 21. Global Hepatitis B Drug Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Hepatitis B Drug Revenue Market Share by Players (2021-2026) Table 23. Global Hepatitis B Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Hepatitis B Drug Key Players Headquarters & Area Served Table 25. Global Hepatitis B Drug Players, Product Type & Application Table 26. Global Hepatitis B Drug Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Hepatitis B Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Hepatitis B Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Hepatitis B Drug Revenue Market Share by Type (2021-2026) Table 33. Global Hepatitis B Drug Revenue Market Share by Type (2027-2032) Table 34. Global Hepatitis B Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Hepatitis B Drug Revenue Market Share by Application (2021-2026) Table 38. Global Hepatitis B Drug Revenue Market Share by Application (2027-2032) Table 39. Bristol-Myers Squibb Company Information Table 40. Bristol-Myers Squibb Business Overview Table 41. Bristol-Myers Squibb Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Bristol-Myers Squibb Hepatitis B Drug Product Portfolio Table 43. Bristol-Myers Squibb Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Gilead Sciences Hepatitis B Drug Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Merck & Co. Inc. Company Information Table 50. Merck & Co. Inc. Business Overview Table 51. Merck & Co. Inc. Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Merck & Co. Inc. Hepatitis B Drug Product Portfolio Table 53. Merck & Co. Inc. Recent Development Table 54. Mitsubishi Tanabe Pharma Company Information Table 55. Mitsubishi Tanabe Pharma Business Overview Table 56. Mitsubishi Tanabe Pharma Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Mitsubishi Tanabe Pharma Hepatitis B Drug Product Portfolio Table 58. Mitsubishi Tanabe Pharma Recent Development Table 59. AbbVie Company Information Table 60. AbbVie Business Overview Table 61. AbbVie Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. AbbVie Hepatitis B Drug Product Portfolio Table 63. AbbVie Recent Development Table 64. GlaxoSmithKline Company Information Table 65. GlaxoSmithKline Business Overview Table 66. GlaxoSmithKline Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. GlaxoSmithKline Hepatitis B Drug Product Portfolio Table 68. GlaxoSmithKline Recent Development Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Roche Hepatitis B Drug Product Portfolio Table 73. Roche Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Novartis Hepatitis B Drug Product Portfolio Table 78. Novartis Recent Development Table 79. Johnson & Johnson Company Information Table 80. Johnson & Johnson Business Overview Table 81. Johnson & Johnson Hepatitis B Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Johnson & Johnson Hepatitis B Drug Product Portfolio Table 83. Johnson & Johnson Recent Development Table 84. North America Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 87. North America Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 88. North America Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Hepatitis B Drug Revenue by Country (2021-2026) & (US$ Million) Table 90. North America Hepatitis B Drug Revenue by Country (US$ Million) & (2027-2032) Table 91. Europe Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 92. Europe Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 93. Europe Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 94. Europe Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 95. Europe Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Hepatitis B Drug Revenue by Country (2021-2026) & (US$ Million) Table 97. Europe Hepatitis B Drug Revenue by Country (US$ Million) & (2027-2032) Table 98. China Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 99. China Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 100. China Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 101. China Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. Asia Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. Asia Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. Asia Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Hepatitis B Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Hepatitis B Drug Revenue by Region (US$ Million) & (2021-2026) Table 108. Asia Hepatitis B Drug Revenue by Region (US$ Million) & (2027-2032) Table 109. SAMEA Hepatitis B Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. SAMEA Hepatitis B Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. SAMEA Hepatitis B Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. SAMEA Hepatitis B Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. SAMEA Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. SAMEA Hepatitis B Drug Revenue by Country (2021-2026) & (US$ Million) Table 115. SAMEA Hepatitis B Drug Revenue by Country (US$ Million) & (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Hepatitis B Drug Image Figure 2. Global Hepatitis B Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis B Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tenofovir Image Figure 5. Telbivudine Image Figure 6. Lamivudine Image Figure 7. Entecavir Image Figure 8. Adefovir Image Figure 9. Others Image Figure 10. Global Hepatitis B Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Hepatitis B Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Pharmacies Image Figure 13. Retail Pharmacies & Drug Stores Image Figure 14. Others Image Figure 15. Global Hepatitis B Drug Market Size (US$ Million) & (2021-2032) Figure 16. Global Hepatitis B Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Hepatitis B Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Hepatitis B Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Hepatitis B Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Hepatitis B Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatitis B Drug Revenue Market Share by Type (2021-2032) Figure 23. Global Hepatitis B Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hepatitis B Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Hepatitis B Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Hepatitis B Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Hepatitis B Drug Revenue Share by Type (2021-2032) Figure 28. North America Hepatitis B Drug Revenue Share by Application (2021-2032) Figure 29. North America Hepatitis B Drug Revenue Share by Country (2021-2032) Figure 30. United States Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Hepatitis B Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Hepatitis B Drug Revenue Share by Type (2021-2032) Figure 35. Europe Hepatitis B Drug Revenue Share by Application (2021-2032) Figure 36. Europe Hepatitis B Drug Revenue Share by Country (2021-2032) Figure 37. Germany Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Hepatitis B Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Hepatitis B Drug Revenue Share by Type (2021-2032) Figure 47. China Hepatitis B Drug Revenue Share by Application (2021-2032) Figure 48. Asia Hepatitis B Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Hepatitis B Drug Revenue Share by Type (2021-2032) Figure 50. Asia Hepatitis B Drug Revenue Share by Application (2021-2032) Figure 51. Asia Hepatitis B Drug Revenue Share by Region (2021-2032) Figure 52. Japan Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Hepatitis B Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Hepatitis B Drug Revenue Share by Type (2021-2032) Figure 60. SAMEA Hepatitis B Drug Revenue Share by Application (2021-2032) Figure 61. SAMEA Hepatitis B Drug Revenue Share by Country (2021-2032) Figure 62. Brazil Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Hepatitis B Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Tenofovir
  • Telbivudine
  • Lamivudine
  • Entecavir
  • Adefovir
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma
  • AbbVie
  • GlaxoSmithKline
  • Roche
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hepatitis B Drug Market by Type
  3. 1.2.1 Global Hepatitis B Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tenofovir
  5. 1.2.3 Telbivudine
  6. 1.2.4 Lamivudine
  7. 1.2.5 Entecavir
  8. 1.2.6 Adefovir
  9. 1.2.7 Others
  10. 1.3 Hepatitis B Drug Market by Application
  11. 1.3.1 Global Hepatitis B Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital Pharmacies
  13. 1.3.3 Retail Pharmacies & Drug Stores
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Hepatitis B Drug Market Dynamics
  1. 2.1 Hepatitis B Drug Industry Trends
  2. 2.2 Hepatitis B Drug Industry Drivers
  3. 2.3 Hepatitis B Drug Industry Opportunities and Challenges
  4. 2.4 Hepatitis B Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hepatitis B Drug Market Perspective (2021-2032)
  2. 3.2 Global Hepatitis B Drug Growth Trends by Region
  3. 3.2.1 Global Hepatitis B Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hepatitis B Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Hepatitis B Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hepatitis B Drug Revenue by Players
  2. 4.1.1 Global Hepatitis B Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Hepatitis B Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hepatitis B Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hepatitis B Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hepatitis B Drug Key Players Headquarters & Area Served
  7. 4.4 Global Hepatitis B Drug Players, Product Type & Application
  8. 4.5 Global Hepatitis B Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hepatitis B Drug Market CR5 and HHI
  11. 4.6.3 2025 Hepatitis B Drug Tier 1, Tier 2, and Tier 3
5 Hepatitis B Drug Market Size by Type
  1. 5.1 Global Hepatitis B Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hepatitis B Drug Revenue by Type (2021-2032)
  3. 5.3 Global Hepatitis B Drug Revenue Market Share by Type (2021-2032)
6 Hepatitis B Drug Market Size by Application
  1. 6.1 Global Hepatitis B Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hepatitis B Drug Revenue by Application (2021-2032)
  3. 6.3 Global Hepatitis B Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Hepatitis B Drug Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Gilead Sciences
  8. 7.2.1 Gilead Sciences Company Information
  9. 7.2.2 Gilead Sciences Business Overview
  10. 7.2.3 Gilead Sciences Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Gilead Sciences Hepatitis B Drug Product Portfolio
  12. 7.2.5 Gilead Sciences Recent Developments
  13. 7.3 Merck & Co. Inc.
  14. 7.3.1 Merck & Co. Inc. Company Information
  15. 7.3.2 Merck & Co. Inc. Business Overview
  16. 7.3.3 Merck & Co. Inc. Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co. Inc. Hepatitis B Drug Product Portfolio
  18. 7.3.5 Merck & Co. Inc. Recent Developments
  19. 7.4 Mitsubishi Tanabe Pharma
  20. 7.4.1 Mitsubishi Tanabe Pharma Company Information
  21. 7.4.2 Mitsubishi Tanabe Pharma Business Overview
  22. 7.4.3 Mitsubishi Tanabe Pharma Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mitsubishi Tanabe Pharma Hepatitis B Drug Product Portfolio
  24. 7.4.5 Mitsubishi Tanabe Pharma Recent Developments
  25. 7.5 AbbVie
  26. 7.5.1 AbbVie Company Information
  27. 7.5.2 AbbVie Business Overview
  28. 7.5.3 AbbVie Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie Hepatitis B Drug Product Portfolio
  30. 7.5.5 AbbVie Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Hepatitis B Drug Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Roche Hepatitis B Drug Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Hepatitis B Drug Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Johnson & Johnson
  50. 7.9.1 Johnson & Johnson Company Information
  51. 7.9.2 Johnson & Johnson Business Overview
  52. 7.9.3 Johnson & Johnson Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Johnson & Johnson Hepatitis B Drug Product Portfolio
  54. 7.9.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Hepatitis B Drug Revenue (2021-2032)
  2. 8.2 North America Hepatitis B Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Hepatitis B Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Hepatitis B Drug Revenue by Type (2027-2032)
  5. 8.3 North America Hepatitis B Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Hepatitis B Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Hepatitis B Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Hepatitis B Drug Revenue by Application (2027-2032)
  9. 8.5 North America Hepatitis B Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Hepatitis B Drug Revenue by Country
  11. 8.6.1 North America Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hepatitis B Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Hepatitis B Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Hepatitis B Drug Revenue (2021-2032)
  2. 9.2 Europe Hepatitis B Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hepatitis B Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hepatitis B Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Hepatitis B Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hepatitis B Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hepatitis B Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hepatitis B Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Hepatitis B Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hepatitis B Drug Revenue by Country
  11. 9.6.1 Europe Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hepatitis B Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hepatitis B Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Hepatitis B Drug Revenue (2021-2032)
  2. 10.2 China Hepatitis B Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Hepatitis B Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Hepatitis B Drug Revenue by Type (2027-2032)
  5. 10.3 China Hepatitis B Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Hepatitis B Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Hepatitis B Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Hepatitis B Drug Revenue by Application (2027-2032)
  9. 10.5 China Hepatitis B Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hepatitis B Drug Revenue (2021-2032)
  2. 11.2 Asia Hepatitis B Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hepatitis B Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hepatitis B Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Hepatitis B Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hepatitis B Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hepatitis B Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hepatitis B Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Hepatitis B Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hepatitis B Drug Revenue by Country
  11. 11.6.1 Asia Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hepatitis B Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hepatitis B Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hepatitis B Drug Revenue (2021-2032)
  2. 12.2 SAMEA Hepatitis B Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hepatitis B Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hepatitis B Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hepatitis B Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hepatitis B Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hepatitis B Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hepatitis B Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hepatitis B Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hepatitis B Drug Revenue by Country
  11. 12.6.1 SAMEA Hepatitis B Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hepatitis B Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hepatitis B Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst